1 Wirth A, Weber E, Huber L. Rhabdomyolyse – une maladie aux multiples causes possible. Forum Med Suisse. 2019;19(35–36):596–8.
2 Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–90.
3 McMahon GM, Zeng X, Waikar SS. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med. 2013;173(19):1821–8.
4 Guemara R, Lazarou I, Guerne I-A. Myopathies médicamenteuses. Rev Med Suisse. 2017;13(562):1013–1017.
5 Dalugama C, Pathirage M, Kularatne S. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. J Med Case Rep. 2018;12(1):143.
6 Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95(1):120–2.
7 Wang D, Wang Y. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review. Medicine (Baltimore). 2018;97(14):e0318.
8 Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia – a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–6.
9 Harrois A. Rhabdomyolyse et insuffisance rénale aigue. In: Communications scientifiques. MAPAR 2017: 35e Journées Internationales de Mises Au Point en Anesthésie-Réanimation, 2017 9–10 Jun, Paris, France 2017, p. 393–407.
10 Kosinski C, Tran C, Kuntzer T, Rodondi N, Collet TH. Symptômes musculaires associés aux statines: quelle prise en charge en 2018? Rev Med Suisse. 2018;14(596):462–9.